Furthermore, SMYD3 has been previously linked to cancer resistance to chemotherapy (43), and we previously showed that SMYD3 inhibition can potentiate the efficacy of a MEK inhibitor in the context of RAS-induced lung adenocarcinoma (18). This evidence concerns the gene MAP2K7 and cancer.